Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of “Moderate Buy” from Brokerages

Posted by on Sep 29th, 2026

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have been given an average rating of “Moderate Buy” by the twenty-three research firms that are presently covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $367.20.

Several equities research analysts have recently issued reports on the company. Royal Bank Of Canada reduced their price target on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Citigroup dropped their price objective on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. TD Cowen reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st.

Get Our Latest Research Report on ALNY

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of Nova Scotia grew its holdings in shares of Alnylam Pharmaceuticals by 0.6% during the 1st quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company’s stock worth $2,580,000 after purchasing an additional 49 shares in the last quarter. Prestige Wealth Management Group LLC raised its stake in Alnylam Pharmaceuticals by 30.6% in the first quarter. Prestige Wealth Management Group LLC now owns 226 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 53 shares in the last quarter. Glenmede Trust Co. NA raised its stake in Alnylam Pharmaceuticals by 8.3% in the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 56 shares in the last quarter. MV Capital Management Inc. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $25,000. Finally, Parallel Advisors LLC lifted its position in Alnylam Pharmaceuticals by 7.9% during the first quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 65 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.2%

NASDAQ ALNY opened at $255.36 on Tuesday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals has a 1-year low of $197.81 and a 1-year high of $495.55. The firm’s fifty day simple moving average is $243.92 and its 200-day simple moving average is $282.60. The company has a market capitalization of $34.17 billion, a PE ratio of 47.46 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter last year, the firm earned ($0.51) earnings per share. The business’s revenue for the quarter was up 66.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals will post 6.71 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).

Read More

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.